Efficacy and safety of daggliflozin in the treatment of elderly type 2 diabetes patients with heart failure with preserved ejection fraction
Objective To observe the therapeutic value and safety of daggligin in elderly patients with type 2 diabetes complicated with heart failure with preserved ejection fraction(HFpEF).Methods A total of 130 elderly patients with HFpEF from March 2020 to August 2022 were included and were randomly divided into a control group and a daggliflozin group,with 65 cases in each group.Both groups received standard heart failure treatment.The control group received oral metformin with insulin added if blood sugar control was poor;while the Daggliflozin group received Daggliflozin at an increased dosage of 10 mg/day on top of the control group treatment.NT ProBNP levels,Minnesota heart failure quality of life questionnaire(MLHFQ)scores,left ventricular ejection fraction(LVEF),left atrial volume index(LAVI),and left ventricular early diastolic mitral flow maximum velocity/early diastolic mitral ring peak velocity(E/e')between the two groups before and 12 months after treatment were compared.Compare the cardiovascular mortality rate,readmission rate due to HF,and adverse reactions between the two groups during the 12 month period.Results 64 cases in the control group and 3 cases in the daggliflozin group were unable to complete the study.After treatment,the NT ProBNP levels and MLHFQ scores in both groups decreased.The NT ProBNP levels and MLHFQ scores in the dapagliflozin group were(652.9±114.6)pg/ml and(48.4±8.1),respectively,lower than the control group's(943.1±101.7)pg/ml and(52.6±8.9),with statistically significant differences between the groups(t=15.099,2.780,P<0.05),and LAVI in the dapagliflozin group was(31.3±3.8)ml/m2,Although E/e'(11.9±2.9)was lower than the control group's(32.6±3.7)ml/m2 and(12.7±2.3),there was no statistically significant difference between the groups(t=1.953,1.723,P>0.05).The readmission rate for heart failure in the dapagliflozin group was 12.69%,lower than the control group's 26.56%(χ2=3.859,P=0.049).The cardiovascular mortality rate and incidence of adverse reactions in the two groups were 0.02%vs.0%,9.52%vs.6.25%(χ2=0.001,0.469,P>0.05).Conclusion In elderly HFpEF patients with type 2 diabetes,adding daggligin to conventional treatment can improve quality of life,reduce the risk of HF readmission,and exhibit acceptable adverse reactions.
Heart failureHeart failure with preserved ejection fractionDapagliptinElderly
NETL
NSTL
万方数据
